P
Paul O'Connor
Researcher at University of Toronto
Publications - 120
Citations - 21759
Paul O'Connor is an academic researcher from University of Toronto. The author has contributed to research in topics: Teriflunomide & Multiple sclerosis. The author has an hindex of 47, co-authored 120 publications receiving 19945 citations. Previous affiliations of Paul O'Connor include St. Michael's GAA, Sligo & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H. Polman,Stephen C. Reingold,Gilles Edan,Massimo Filippi,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Luanne M. Metz,Henry F. McFarland,Paul O'Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Brian G. Weinshenker,Jerry S. Wolinsky +13 more
TL;DR: New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.
Journal ArticleDOI
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos,Ernst Wilhelm Radue,Paul O'Connor,Chris H. Polman,Reinhard Hohlfeld,Peter A. Calabresi,Krzysztof Selmaj,Catherine Agoropoulou,Malgorzata Leyk,Lixin Zhang-Auberson,Pascale Burtin +10 more
TL;DR: Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.
Journal ArticleDOI
Defining the clinical course of multiple sclerosis: The 2013 revisions
Fred D. Lublin,Stephen C. Reingold,Jeffrey A. Cohen,Gary Cutter,Per Soelberg Sørensen,Alan J. Thompson,Jerry S. Wolinsky,Laura J. Balcer,Brenda Banwell,Frederik Barkhof,Bruce F. Bebo,Peter A. Calabresi,Michel Clanet,Giancarlo Comi,Robert J. Fox,Mark S. Freedman,Andrew D. Goodman,Matilde Inglese,Ludwig Kappos,Bernd C. Kieseier,John A. Lincoln,Catherine Lubetzki,Aaron E. Miller,Xavier Montalban,Paul O'Connor,John Petkau,Carlo Pozzilli,Richard A. Rudick,Maria Pia Sormani,Olaf Stüve,Emmanuelle Waubant,Chris H. Polman +31 more
TL;DR: Refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression are proposed and strategies for future research to better define phenotypes are outlined.
Journal ArticleDOI
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
David Miller,Omar Khan,William A. Sheremata,Lance D Blumhardt,George P.A. Rice,Michele A Libonati,Allison J Willmer-Hulme,Catherine M. Dalton,Katherine A. Miszkiel,Paul O'Connor +9 more
TL;DR: In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.
Journal ArticleDOI
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Ludwig Kappos,Jack P. Antel,Giancarlo Comi,Xavier Montalban,Paul O'Connor,Chris H. Polman,Tomas Haas,Alexander Korn,Goeril Karlsson,Ernst Wilhelm Radue +9 more
TL;DR: In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis and both measures decreased in patients who switched from placebo to fingolIMod.